Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 11/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 11/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195022 | 0.89 | HTR1A (0.52) | DRD2DRD3ADRA1AADRA1BADRA1D | |
| SCHEMBL7058962 | 0.80 | KMT2A (0.51) | DRD2DRD3ADRA1AADRA1BADRA1D | |
| SCHEMBL6195674 | 0.76 | MAPK1 (0.53) | DRD2DRD3ADRA1AADRA1BADRA1D | |
| SCHEMBL6195742 | 0.73 | DRD2 (0.55) | DRD2DRD3ADRA1AHTR1AHTR7 | |
| SCHEMBL6192022 | 0.72 | NPC1 (0.67) | DRD2DRD3ADRA1AADRA1BADRA1D | |
| SCHEMBL6752995 | 0.72 | MCHR1 (0.47) | DRD2DRD3ADRA1AADRA1BADRA1D | |
| SCHEMBL24712880 | 0.70 | DRD2 (0.59) | DRD2DRD3ADRA1AADRA1BADRA1D | |
| SCHEMBL4808090 | 0.69 | SLC6A2 (0.50) | — | |
| SCHEMBL12962208 | 0.69 | NPC1 (0.61) | DRD2DRD3ADRA1AADRA1BADRA1D | |
| SCHEMBL7835709 | 0.69 | ADRA1A (0.60) | DRD2DRD3ADRA1AADRA1BADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432701-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI IRELAND LTD (IE) | 2005-12-21 | — | — | EP | disclosed |
| US-20030181446-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-09-25 | — | — | US | disclosed |
| US-20030162777-A1 | Novel N-acylated heterocycles | RECORDATI S.A. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162777-A1 | Novel N-acylated heterocycles | HTR1A, HTR1D, HTR1E | DRD2 163/4885DRD3 177/4885ADRA1A 36/4885 |
| US-20030181446-A1 | Novel N-acylated heterocycles | HTR1A, HTR1E, HTR2C | DRD2 85/4885DRD3 95/4885ADRA1A 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.